{
  "pmcid": "9266992",
  "sha256": "3e63fdb43bce72f0b38368377e9eb075ffef8b98de357b9af28bd92062f84417",
  "timestamp_utc": "2025-11-09T16:20:52.390420+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.991601951219511,
    "reading_ease": 36.23987902439026,
    "word_count": 625
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "We included all randomised controlled trials (RCTs) of CLI in which participants were randomly allocated to intramuscular administration of autologous adult BMMNCs or control."
      },
      "Participants": {
        "score": 2,
        "evidence": "We included four RCTs involving a total of 176 participants with a clinical diagnosis of CLI."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either intramuscular cell implantation of BMMNCs or control."
      },
      "Objective": {
        "score": 1,
        "evidence": "To evaluate the benefits and harms of local intramuscular transplantation of autologous adult bone marrow mononuclear cells (BMMNCs) as a treatment for CLI."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Our primary outcomes of interest were all‐cause mortality, pain, and amputation."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "We included four RCTs involving a total of 176 participants with a clinical diagnosis of CLI."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "There was no clear evidence of an effect on mortality related to the administration of BMMNCs compared to control (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.15 to 6.63; 3 studies, 123 participants; very low‐certainty evidence)."
      },
      "Harms": {
        "score": 1,
        "evidence": "We pooled the data for side effects reported during the follow‐up, and this did not show any clear difference between BMMNC and control groups (RR 2.13, 95% CI 0.50 to 8.97; 4 studies, 176 participants; very low‐certainty evidence)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}